A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

Condition:   Squamous Cell Carcinoma of Head and Neck
Interventions:   Drug: Cisplatin;   Drug: Nivolumab;   Radiation: RT
Sponsors:   Groupe Oncologie Radiotherapie Tete et Cou;   Bristol-Myers Squibb
Not yet recruiting

https://ift.tt/2MHqwem